BridgeBio Pharma, Inc. (BBIO) Q4 FY25 Earnings Call

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-02-25
Length51 minutes
EPS$1.00
Revenue$154.2M
Revenue consensus$148.1M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q1 FY26

All BBIO earnings ยท Back to BBIO overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.